Editorial Note: We earn a commission from partner links on Forbes Advisor. Commissions do not affect our editors' opinions or evaluations. Web hosts and website builders make building a website ...

BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the shares ahead of earnings. For the Cystic Fibrosis ...

Vertex just won approval for a drug to treat ... Opioid prices generally are lower, but they do vary. That said, two things could support the uptake of Journavx. One is the company's efforts ...

Editorial Note: We earn a commission from partner links on Forbes Advisor. Commissions do not affect our editors' opinions or evaluations. Shoestring budgets are all too common for SMBs ...

Here's everything you need to know about capturing screenshots on your Windows PC, Android device, Mac, iPhone, Chromebook, and even a Vision Pro headset.

Drowning patients are probably the most dangerous patients to try to rescue. In a panic, drowning patients are likely to claw at rescuers and climb to the surface at all costs. NEVER attempt a direct ...

Trading options requires answering these questions: Which direction will a stock move, how far will it go and when will it happen? Here are 4 steps to get started. Many, or all, of the products ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Get prepared with the key expectations. Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...